Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1GSK3AGSK3BHRH1HRH2HTR7IDH1IDH2IMPA1IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | HMGCR | P04035 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL18584347 | 0.98 | TSHR (0.54) | TSHRALDH1A1LMNAAPEX1CA4 | |
| Citric Acid SCHEMBL10728752 | 0.98 | TSHR (0.54) | TSHRALDH1A1LMNAAPEX1CA4 | |
| Citric Acid SCHEMBL36782 | 0.87 | CA4 (0.52) | TSHRALDH1A1LMNAAPEX1CA4 | |
| Citric Acid SCHEMBL7083476 | 0.85 | CA4 (0.50) | TSHRALDH1A1LMNAAPEX1CA4 | |
| Citric Acid SCHEMBL22229905 | 0.83 | ALDH1A1 (0.65) | TSHRALDH1A1LMNAAPEX1HMGCR | |
| Citric Acid SCHEMBL3683509 | 0.83 | ALDH1A1 (0.54) | TSHRALDH1A1LMNAAPEX1CA4 | |
| Citric Acid SCHEMBL28164924 | 0.83 | CA4 (0.64) | TSHRALDH1A1CA4HMGCRCHRM1 | |
| Citric Acid SCHEMBL107472 | 0.82 | CA4 (0.64) | TSHRALDH1A1LMNAAPEX1CA4 | |
| Citric Acid SCHEMBL119895 | 0.81 | LMNA (0.43) | TSHRALDH1A1LMNAAPEX1CA4 | |
| Citric Acid SCHEMBL33988 | 0.80 | CA4 (0.59) | TSHRALDH1A1CA4HMGCRCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565189-A1 | LIQUID CLEANSING COMPOSITION | Unilever IP Holdings B.V. (NL) | 2025-06-11 | — | — | EP | claimed |
| CN-119639845-A | Synergist and application thereof in fermentation production of xanthan gum | 廊坊梅花生物技术开发有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-119564625-A | Betaine composition with blood pressure lowering effect and preparation method thereof | 山东祥维斯医药科技有限公司 | 2025-03-07 | — | — | CN | claimed |
| EP-4408964-A1 | CLEANSING COMPOSITION | Unilever IP Holdings B.V. (NL) | 2024-08-07 | — | — | EP | claimed |
| EP-4125794-B1 | CLEANSING COMPOSITION | UNILEVER IP HOLDINGS B V (NL) | 2024-02-14 | — | — | EP | claimed |
| WO-2024028058-A1 | LIQUID CLEANSING COMPOSITION | UNILEVER IP HOLDINGS B.V. (NL) | 2024-02-08 | — | — | WO | claimed |
| US-20230414468-A1 | WASH COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2023-12-28 | — | — | US | claimed |
| EP-4243764-A1 | WASH COMPOSITION | Unilever IP Holdings B.V. (NL) | 2023-09-20 | — | — | EP | claimed |
| WO-2023052124-A1 | CLEANSING COMPOSITION | UNILEVER IP HOLDINGS B.V. (NL) | 2023-04-06 | — | — | WO | claimed |
| EP-4125794-A1 | CLEANSING COMPOSITION | Unilever IP Holdings B.V. (NL) | 2023-02-08 | — | — | EP | claimed |
| WO-2022128441-A1 | CLEANSING COMPOSITION | UNILEVER IP HOLDINGS B.V. (NL) | 2022-06-23 | — | — | WO | claimed |
| WO-2022101097-A1 | WASH COMPOSITION | UNILEVER IP HOLDINGS B.V. (NL) | 2022-05-19 | — | — | WO | claimed |
| WO-2021197906-A1 | CLEANSING COMPOSITION | UNILEVER IP HOLDINGS B.V. (NL) | 2021-10-07 | — | — | WO | claimed |
| WO-2021104844-A1 | CLEANSING COMPOSITION | UNILEVER IP HOLDINGS B.V. (NL) | 2021-06-03 | — | — | WO | claimed |
| US-20070280918-A1 | Multitherapy Against Cancer | SCHWARTZ, LAURENT, MR. (FR) | 2007-12-06 | — | — | US | claimed |
| US-4703045-A | BETAINE SALTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 1987-10-27 | — | — | US | claimed |
| US-4593020-A | Betaine citrate | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 1986-06-03 | — | — | US | claimed |
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | Doane Technology Group LLC (US) | 2026-05-26 | — | — | US | disclosed |
| US-4703045-A | BETAINE SALTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 1987-10-27 | — | — | US | disclosed |
| US-4593020-A | Betaine citrate | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 1986-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414468-A1 | WASH COMPOSITION | WASHC5, WASHC4, ABHD16A | TSHR 2517/4885ALDH1A1 2473/4885LMNA 3385/4885 |
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | CNR2, CNR1, LIPC | TSHR 2385/4885ALDH1A1 3717/4885LMNA 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.